Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Baxter Adding $200 Mil. In Critical Care Rx Sales Via ESI Lederle Deal

  • News

Executive Summary

Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth

You may also be interested in...



Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order

A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet
Tags:
UsernamePublicRestriction

Register

PS039999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By